MRSN Mersana Therapeutics Inc.

3.99
+0.02  (+1%)
Previous Close 3.97
Open 3.97
Price To Book 1.53
Market Cap 190,390,259
Shares 47,716,857
Volume 209,750
Short Ratio
Av. Daily Volume 292,774

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Development to be discontinued - noted January 4, 2019.
XMT1522
HER2 - breast cancer
Phase 1 data at ASCO June 1, 2019. 17% PR rate.
XMT-1536
Ovarian Cancer, Non Small Cell Lung Cancer

Latest News

  1. Hedge Funds Have Never Been This Bullish On Mersana Therapeutics, Inc. (MRSN)
  2. Does Mersana Therapeutics, Inc. (NASDAQ:MRSN) Have A Particularly Volatile Share Price?
  3. Mersana Therapeutics Announces Appointment of Brian C. DeSchuytner as Senior Vice President of Finance and Product Strategy
  4. Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting
  5. Mersana Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
  6. Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting
  7. Mersana Therapeutics, Inc. (MRSN) Q1 2019 Earnings Call Transcript
  8. Mersana Therapeutics Announces First Quarter 2019 Financial Results and Provides Business Updates
  9. Mersana Therapeutics to Host Conference Call Announcing First Quarter 2019 Financial Results and Business Updates
  10. Consider These 3 Falling Knives
  11. New Research: Key Drivers of Growth for Liberty Global, KKR Real Estate Finance Trust, AGCO, Model N, STAAR Surgical, and Mersana Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
  12. Mersana Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
  13. Mersana Therapeutics Announces Poster and Presentation at the American Association for Cancer Research Annual Meeting 2019
  14. What Should You Know About Mersana Therapeutics, Inc.’s (NASDAQ:MRSN) Earnings Trajectory?
  15. JPMorgan Downgrades Mersana, Says Data Readouts Unlikely To Reverse Street Sentiment
  16.  Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates
  17. Mersana Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference
  18. Mersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  19. Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2018 Financial Results and Business Updates
  20. The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis